Are Mounjaro and Zepbound the same drug?
Yes. Mounjaro and Zepbound contain exactly the same active ingredient: a medicine called tirzepatide. They are made by the same company, Eli Lilly. The medicine inside the pen is identical — same molecule, same way of working, same dose ladder. There is no chemical difference between them.
So why two names? Because the same drug can be approved for different jobs, and a brand name is tied to a job. Tirzepatide was first approved as Mounjaro for type 2 diabetes. Later, the same tirzepatide was approved under a second name, Zepbound, for weight management — and then for a sleep-breathing condition too. Two brand names, one molecule, different official uses.
If that sounds familiar, it is the same pattern as Ozempic and Wegovy, which are both the drug semaglutide under two names. With tirzepatide the names are Mounjaro and Zepbound. The short version: this is not a "which drug is stronger" question — it is the same drug, labeled twice.
What is actually different between them?
The real difference is the label — the official, FDA-approved use the brand is sold for. A label is the set of uses regulators have reviewed the evidence for and signed off on. Mounjaro and Zepbound carry different labels even though the medicine is the same.
Mounjaro is the version approved for type 2 diabetes. Its job, on paper, is to help control blood sugar in adults who have diabetes. Weight loss often happens too, but blood-sugar control is the approved purpose.
Zepbound is the version approved for chronic weight management — long-term treatment of obesity, or of being overweight with a weight-related health problem. In December 2024 Zepbound also gained a second approved use: moderate-to-severe obstructive sleep apnea in adults with obesity, a condition where breathing repeatedly stops and starts during sleep. So the difference between the two brands is not what is in the syringe — it is what each one is officially approved to treat.
Why does that distinction matter if the drug is the same? Because an approved use is the thing regulators have actually studied and signed off on for safety and benefit. The label tells a clinician which job the evidence supports, and it shapes how the medicine is prescribed, dispensed, and covered. The molecule being identical does not erase the line between "approved to treat diabetes" and "approved to treat obesity and sleep apnea" — those are separate official permissions, even for one drug.
Do they work the same way in the body?
They do, because they are the same molecule. Tirzepatide is what scientists call a dual agonist. That means it copies and switches on two natural gut hormones at once: GLP-1 and GIP. A hormone is just a chemical messenger that travels in your blood; GLP-1 and GIP are two of the messages your gut sends after you eat.
GLP-1 is the well-known "I am full" signal — it tells your brain you have eaten enough and tells your stomach to empty more slowly. GIP is a second gut signal that works alongside it and also affects how the body handles sugar and fat. By turning up both signals, tirzepatide lowers appetite, steadies blood sugar, and helps the body lose weight. It does the same thing whether the pen says Mounjaro or Zepbound.
Activating two gut signals at once is what sets tirzepatide apart from older drugs that copy only GLP-1, and it is part of why it produced such strong results in trials. But that "two signals" design is a property of the molecule, not of the brand. Mounjaro and Zepbound are both that same two-signal molecule, so both deliver the same combined effect.
Because the mechanism is identical, the everyday experience of the medicine — how it curbs hunger, how it is injected, how often — is the same for both. The brand name does not change the biology.
Is the dose the same for Mounjaro and Zepbound?
The dose ladder is the same for both, because it is the same drug. Treatment starts low and steps up slowly. The starting dose is 2.5 mg, injected under the skin once a week. This first dose is a warm-up meant to let your stomach get used to the medicine — it is not the dose that does the main work.
After four weeks the dose goes up to 5 mg once weekly. From there it can be raised in 2.5 mg steps, but no sooner than every four weeks, giving the body time to adjust at each level. The approved maintenance doses — the ones meant for the long term — are 5 mg, 10 mg, or 15 mg once weekly, and the maximum is 15 mg weekly.
This slow climb is on purpose. Going up gradually is what keeps the stomach side effects manageable, and it applies the same way for diabetes (Mounjaro) and for weight or sleep apnea (Zepbound). Where a person lands on that ladder is a decision a clinician makes based on how they respond and tolerate it.
One practical note: not everyone needs to reach 15 mg. Some people do well and stay on 5 mg or 10 mg, while others climb to the top dose. The right maintenance dose is the lowest one that gives a good result with side effects a person can live with — and that target is the same whether the prescription says Mounjaro or Zepbound, because the medicine and the ladder are identical.
How much weight loss does tirzepatide produce?
The weight-loss evidence comes mainly from a large trial called SURMOUNT-1, which tested tirzepatide in adults with obesity (but not diabetes) over 72 weeks. At the highest dose, 15 mg once weekly, participants lost about 20.9% of their body weight on average, compared with about 3.1% on placebo — placebo being a dummy injection with no medicine.
The trial also looked at how many people hit meaningful targets, not just the average. At the 15 mg dose, about 91% of participants lost at least 5% of their body weight, and roughly 57% lost at least 20%. Those are large numbers for a medicine, and they are why tirzepatide drew so much attention as a weight treatment.
It helps to know what an average like that does and does not promise. An average means some people lost more and some lost less; it is not a number anyone is guaranteed to hit. Results depend on the dose reached, how long someone stays on the medicine, and the diet and activity changes alongside it. What the trial does show clearly is that, as a group, tirzepatide moved most people well past clinically meaningful weight-loss thresholds.
This evidence is what supported the Zepbound approval for weight management. It is the same tirzepatide that is in Mounjaro — but weight management is Zepbound's labeled job, which is why the weight data live under that brand.
How well does it control blood sugar in diabetes?
For type 2 diabetes, the headline measure is HbA1c. HbA1c is a blood test that shows your average blood sugar over the past two to three months — the lower the number, the better the control, and even a one-point drop is meaningful.
In a trial called SURPASS-2, tirzepatide was compared head-to-head against semaglutide (the drug in Ozempic) over 40 weeks in people with type 2 diabetes. Tirzepatide lowered HbA1c by about 2.0 percentage points at the 5 mg dose, 2.2 points at 10 mg, and 2.3 points at 15 mg — somewhat more than semaglutide, which lowered it by about 1.9 points. People on tirzepatide also lost more weight.
This blood-sugar evidence is what underpins the Mounjaro approval for type 2 diabetes. Again, it is the very same molecule as Zepbound — the diabetes data simply sit under the Mounjaro label because diabetes is Mounjaro's approved use.
What is the sleep-apnea approval about?
In December 2024, Zepbound earned a third use that neither brand had before: treating moderate-to-severe obstructive sleep apnea in adults who also have obesity. Obstructive sleep apnea, or OSA, is a condition where the airway repeatedly collapses during sleep, so breathing stops and starts through the night, leaving people tired and at higher health risk.
The approval was based on a trial called SURMOUNT-OSA. Doctors measure sleep apnea with the apnea-hypopnea index, or AHI — the number of times breathing pauses or goes shallow per hour of sleep. In the trial, tirzepatide cut that number sharply: AHI fell by roughly 20 to 24 more events per hour than on placebo, depending on the group. Many participants improved enough that their sleep apnea became mild or non-symptomatic.
This made tirzepatide the first medicine the FDA approved for obstructive sleep apnea. It is meant to be used alongside a reduced-calorie diet and more activity, and it treats OSA largely by reducing the obesity that drives it — not as a swap for a diagnosis or for a CPAP machine. This use is labeled under Zepbound, not Mounjaro.
This is the clearest single example of why the two brands exist. The exact same molecule that controls blood sugar under the Mounjaro label, and drives weight loss under the Zepbound label, also eases sleep apnea — but only the Zepbound label carries the sleep-apnea approval. A person with sleep apnea and obesity who might benefit is, on paper, a candidate for the Zepbound version, and that match between condition and label is the prescriber's job to make.
Are the side effects the same?
Yes — because it is the same drug, the side-effect profile is the same for Mounjaro and Zepbound. The most common effects are in the stomach and gut: nausea, diarrhea, vomiting, and constipation. These tend to be strongest at the start and just after a dose is raised, and they usually ease as the body adjusts to the slow dose climb.
A few simple habits make the early weeks easier for most people: eating smaller meals, stopping when comfortably full rather than stuffed, and going easy on greasy or very rich food while the stomach is adjusting. Drinking enough water matters too, because vomiting or diarrhea can leave a person dehydrated. None of this is unique to one brand — it is the same advice on tirzepatide whether the label reads Mounjaro or Zepbound.
There are also more serious warnings that apply to tirzepatide as a medicine — for example, around the pancreas, gallbladder, and a thyroid-tumor warning carried by this drug class — and it is not suitable for everyone. None of this changes between the two brands. The safety considerations belong to tirzepatide, whichever name is on the pen, and they are exactly the kind of thing a clinician weighs before prescribing.
Why can't you just swap the label?
It is natural to think that if Mounjaro and Zepbound are the same drug, they are freely interchangeable. They are the same molecule — but the brands are not casually swappable, and the reason is the label rather than the chemistry.
A brand is approved, prescribed, and dispensed for a specific use. Mounjaro is the route for treating type 2 diabetes; Zepbound is the route for weight management and sleep apnea. Which brand a person is prescribed depends on their diagnosis and what a clinician is treating, and that decision sits with the prescriber — not with the patient picking a name. Pharmacies, prescriptions, and coverage are all built around the approved use, so the two are not simply traded one-for-one even though the contents match.
The takeaway is simple: same medicine, two labels, and the label is what a clinician matches to the person in front of them. This page explains the distinction; it is not medical advice, and it is not a recommendation to start, stop, or switch anything. That conversation belongs with a licensed clinician.
Tracking tirzepatide on PeptidePanel
Whether a clinician prescribes the Mounjaro or the Zepbound version, the day-to-day work of being on tirzepatide is the same: log each weekly dose, watch the numbers that matter (HbA1c, weight trend, blood pressure, lipids), and catch side effects early. PeptidePanel is the neutral tracking layer for exactly that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
Because the medicine is the same across both brands, the tracking does not change if a clinician ever moves a person from one label to the other — the dose history, the weekly reminders, and the biomarker charts carry straight over. The point of a tracking layer is to keep that whole picture in one place, so a person and their clinician can see how things are actually going over weeks and months rather than relying on memory.
PeptidePanel does not sell, source, or supply tirzepatide or any other medicine, and it does not pick a brand for you. It is a monitoring tool for a plan a qualified prescriber has already put you on.